European expansion Panpharma is actively modernizing and expanding production capacity in France and Germany, with recent multi-million euro investments to double injectable antibiotic, anesthetic, and analgesic output. This creates opportunities to discuss supply chain resilience, contract manufacturing, and regional line extensions for hospitals and clinics across Europe.

injectable portfolio The company specializes in generic injectable antibiotics, anesthetics, and analgesics for hospitals and clinics across 75+ countries. Sales opportunities exist in expanding hospital formularies, unit-dose vial launches, and cross-border tender collaborations with European public health systems and international distributors.

sustained demand With a 40-year mission to ensure reliable access to essential medicines and a focus on critical injectables, Panpharma targets steady demand from healthcare facilities. This supports upsell scenarios for expanded product lines, patient-care continuity programs, and long-term supply agreements.

tech enabled Panpharma utilizes SAP, Infor, Microsoft Dynamics, and analytics tools like Power BI, alongsideData privacy and web platforms. This indicates readiness for integrated ERP-driven procurement partnerships, digital order management, and transparent compliance reporting to large hospital networks.

stable foundation As an ETI family-owned French group with 600+ employees and a robust production footprint, Panpharma offers a reliable partner profile for distributors and healthcare groups seeking stable, long-term collaboration, especially for high-volume injectable portfolios and regional manufacturing commitments.